Top Manchester Biotech Companies (12)
Don't see your company?
Create a company profile
Blueberry Therapeutics Ltd. is a modern drug discovery and development company which puts people first whether patients, employees, investors or partners. We have created an open, imaginative and fun team environment with a very serious objective: to create new, safer and more effective medicines to treat human disease and make patients feel better. Blueberry focuses on the research and development of treatments for skin diseases. We do this by employing state of the art preclinical research technologies to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic. In the clinic, Blueberry uses smart, agile, clinical designs to deliver high quality trials more rapidly and with reduced development costs. Blueberry will rapidly progress new therapies to clinical proof-of-concepts and beyond with appropriate, effective and safe doses with full regulatory and ethical approval. We have programs addressing Onychomycosis, Tinea Pedis, Acne and Atopic Dermatitis.
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by providing the most novel knowledge graph in biopharma for better knowledge review, target and biomarker discovery, mechanism of action understanding, and indication expansion
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care.
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim is in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA. F2G is headquartered in the UK with subsidiaries in the US and Austria.
Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by providing the most novel knowledge graph in biopharma for better knowledge review, target and biomarker discovery, mechanism of action understanding, and indication expansion
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Together, our experts help clients connect patients with life-changing therapies, realizing the potential of strategies and solutions to accelerate innovation that improves lives.
APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.
Welcome to Bright Biotech, where innovation meets purpose, and a brighter future comes to life! We are revolutionising protein production through plant chloroplast technology. Our mission is to deliver ultra-scalable, affordable, and sustainable proteins by transforming plant chloroplasts into high-yield natural bioreactors. Rooted in our commitment to impact and #sustainability, we dedicate our novel #molecularfarming technology to deliver products and solutions that drive the growth of #cellularagriculture, #regenerativemedicine, and more. Our team is at the heart of everything we do. We foster a culture of passion, creativity and integrity. We thrive on collaboration, where every member is valued and empowered to innovate. We are committed to caring for the environment, promoting health, and practicing sustainability to create a positive impact. Together, we are pushing boundaries and scale new heights, always driven by the shared goal of shaping a brighter and more sustainable future for generations to come. #Sustainability #MolecularFarming #Proteins #CultivateMeat #LifeSciences #HighYield #Chloroplast #ProteinProduction #EfficientResources #AffordableProteins #BrightBiotech #NoGeneEnvironmentalnteraction #Innovation #VerticalFarming #ChloroplastsAsBioreactors #PlantTechnology #BrighterFuture #GrowFactors #CellularAgriculture #RegenaritiveMedicine #HyperExpression #SuperiorContainement #EcoFriendly #UltraScalable #EnvironmentalStewardship #RecombinantGrowthFactors #ChloroplastBiotechnology #CellBasedMeat
At Imperagen we are transforming enzyme engineering, digitalising every step of the development pipeline. Our breakthrough technology combines AI powered hotspot prediction with precision DNA editing, fully integrated through end-to-end automation. We have completely reimagined and simplified enzyme development to make it far more rapid, routine, and scalable. Through digitalisation, we reduce the complexity, ensuring your breakthrough products reach the market faster, transforming your enzyme challenges into market-ready solutions.
Analytical scientists and clinical researchers worldwide rely on Agilent to help fulfill their most complex laboratory demands. Our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. Whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, Agilent provides laboratory solutions to meet their full spectrum of needs. We work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. Our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. Customers trust Agilent for solutions that enable insights...for a better world.
Holiferm develops processes for and manufactures innovative, green and sustainable biosurfactants. With a 1.1 ktonne scale biosurfactant manufacturing plant in Liverpool and a bespoke research and development facility in Manchester, Holiferm is suited to meet all your manufacturing and development needs. Our dedicated Customer Technical Support Team is always on hand to help you incorporate our sustainable biosurfactants into your formulations.
Work Your Passion. Live Your Purpose.
